Atopic Dermatitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, NDA, IND, Treatment market, ROA, MOA and Companies by DelveInsight | Nestle, Pfizer, GlaxoSmithKline, Regeneron Pharmaceutical, Abbvie, Allergan, Bausch Health Compa

(Albany, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atopic Dermatitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.

The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Atopic Dermatitis Pipeline Report:
• Atopic Dermatitis Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years.
• Atopic Dermatitis companies working in the treatment market are Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment
• Emerging Atopic Dermatitis therapies in the different phases of clinical trials are- PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
• In March 2024, Sanofi has reported promising results from the second phase of a study involving the OX40 antibody amlitelimab, demonstrating sustained improvement in treating moderate to severe atopic dermatitis symptoms in patients who had previously received treatment.
• In December 2024, Astria Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist. The company is developing STAR-0310 as a potential treatment for atopic dermatitis (AD) and other indications.
• On November 5, 2024, Organon announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) of VTAMA® (tapinarof) cream, 1%, for treating atopic dermatitis in adults and children over two years old. The new target action date is now set for March 12, 2025, a three-month extension from the original date of December 12, 2024.

Atopic Dermatitis Overview
Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It is one of the most prevalent skin disorders, affecting both children and adults, with a higher incidence in individuals with a family history of allergies, asthma, or hay fever. The exact cause of AD is multifactorial, involving genetic predisposition, immune system dysfunction, skin barrier defects, and environmental triggers.

Atopic Dermatitis Symptoms include persistent itching, redness, swelling, and skin thickening due to repeated scratching. The condition often appears on the face, hands, elbows, and knees in children, while adults may develop it on the hands, neck, and eyelids. Flare-ups can be triggered by allergens, stress, irritants, weather changes, or infections.

Atopic Dermatitis Diagnosis is based on clinical evaluation, medical history, and the exclusion of other skin conditions. Atopic Dermatitis Treatment focuses on managing symptoms through moisturizing, topical corticosteroids, calcineurin inhibitors, and antihistamines. In severe cases, systemic immunosuppressants or biologic therapies like dupilumab are used.

While atopic dermatitis is not contagious, it significantly impacts the quality of life due to discomfort and sleep disturbances. Ongoing research aims to develop targeted therapies to provide long-term relief and improve patient outcomes.

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
• PF 07242813: Pfizer
• KT-474: Kymera Therapeutics
• BEN2293: BenevolentAI
• MEDI3506: AstraZeneca
• Q301: Qurient
• SB011: Sterna Biologicals
• Tradipitant: Vanda Pharmaceuticals
• Roflumilast: Arcutis Biotherapeutics

Atopic Dermatitis Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Atopic Dermatitis Molecule Type
Atopic Dermatitis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Atopic Dermatitis Pipeline Therapeutics Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type

DelveInsight's Atopic Dermatitis Report covers around 110+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies at:
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Atopic Dermatitis Therapeutics Market include:
Key companies developing therapies for Atopic Dermatitis are - GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regenron Pharmaceutical Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others.

Atopic Dermatitis Pipeline Analysis:
The Atopic Dermatitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
• Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies-
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Atopic Dermatitis Pipeline Market Drivers
• Rising prevalence of AD, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.

Atopic Dermatitis Pipeline Market Barriers
• However, over-the-counter medications, outdated treatment recommendations • Poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.

Scope of Atopic Dermatitis Pipeline Drug Insight
• Coverage: Global
• Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
• Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others
• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Atopic Dermatitis Report Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis Overview
4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5. Atopic Dermatitis Pipeline Therapeutics
6. Atopic Dermatitis Late Stage Products (Phase II/III)
7. Atopic Dermatitis Mid Stage Products (Phase II)
8. Atopic Dermatitis Early Stage Products (Phase I)
9. Atopic Dermatitis Preclinical Stage Products
10. Atopic Dermatitis Therapeutics Assessment
11. Atopic Dermatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atopic Dermatitis Key Companies
14. Atopic Dermatitis Key Products
15. Atopic Dermatitis Unmet Needs
16 . Atopic Dermatitis Market Drivers and Barriers
17. Atopic Dermatitis Future Perspectives and Conclusion
18. Atopic Dermatitis Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Ada-scid Competitive Landscape: https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
Case Study: https://www.delveinsight.com/case-study/competitive-intelligence

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.